Who We Are
Our support group offers patients and their supporters a place to go for shelter and comfort in dealing with myeloma.
What We Do
Create and share hope with Myeloma patients, caregivers, family and friends through education, support and our personal experiences.
- FDA Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of MM in Patients Who Have Received One or More Prior Therapies
- Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in Study
- 2 Top Medical Journals Weigh in on Potential Danger of Toxic Chemicals
IMF Support Group Network